Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5361897 | 0.87 | KMT2A (0.43) | LMNAALDH1A1HTTKDM4EHPGD | |
| SCHEMBL5760942 | 0.84 | KMT2A (0.45) | LMNAALDH1A1HTTKDM4EHPGD | |
| SCHEMBL5761411 | 0.80 | ALDH1A1 (0.38) | PTGDR2LMNAALDH1A1HTTKDM4E | |
| SCHEMBL5760908 | 0.79 | GAA (0.43) | LMNAALDH1A1HTTKDM4EHPGD | |
| SCHEMBL3391374 | 0.75 | PPARG (0.48) | LMNAALDH1A1HTTGAAKMT2A | |
| SCHEMBL3391356 | 0.75 | GAA (0.52) | LMNAALDH1A1HTTKDM4EHPGD | |
| SCHEMBL5763384 | 0.74 | LMNA (0.52) | LMNAALDH1A1GAAKMT2A | |
| SCHEMBL5762956 | 0.72 | KMT2A (0.44) | LMNAALDH1A1HTTKDM4EHPGD | |
| SCHEMBL5761722 | 0.71 | GAA (0.56) | LMNAALDH1A1GAAKMT2A | |
| SCHEMBL5761990 | 0.71 | KMT2A (0.50) | LMNAALDH1A1HTTKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6897227-B2 | Prodrugs of proton pump inhibitors | Winston Pharmaceuticals, Inc. (US) | 2005-05-24 | — | — | US | disclosed |
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ALEVIUM PHARMACEUTICALS, INC. | 2004-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102484-A1 | Prodrugs of proton pump inhibitors | ABCB11, SLC10A2, SI | PTGDR2 662/4885LMNA 4395/4885ALDH1A1 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.